Acumen Pharmaceuticals: A Speculative Buy Ahead Of November's Alzheimer's Readout

Acumen Pharmaceuticals is rated a speculative Buy ahead of November 2026 Phase 2 ALTITUDE-AD data for sabirnetug in early Alzheimer's disease. I estimate ABOS fair value at $2.57 per share, a 14% premium to market, based on risk-adjusted NPV and anticipated financing needs. Key upside hinges on sabirnetug achieving ≥30% iADRS slowing with manageable ARIA risk; subpar efficacy or safety would negate the thesis.

Seeking Alpha • Oct 28, 2026

Acumen Pharmaceuticals Q3 Earnings Call Highlights

Acumen Pharmaceuticals NASDAQ: ABOS said it expects to report top-line results in November from its Phase II ALTITUDE-AD trial of sabirnetug, an investigational antibody designed to target soluble amyloid-beta oligomers in patients with Alzheimer's disease.

MarketBeat • Oct 26, 2026

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2026 Earnings Call Transcript

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2026 Earnings Call Transcript

Seeking Alpha • Oct 26, 2026

Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in November 2026 IND filing for the Enhanced Brain Delivery™ (EBD®) program lead clinical candidate targeted for mid-2027 Cash, cash equivalents and marketable securities of $78.6 million as of September 30, 2026, expected to support current clinical and operational activities into early 2027 Company to host conference call and webcast today at 8:00 a.m. ET NEWTON, Mass.

GlobeNewsWire • Oct 26, 2026

Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference

NEWTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), will present three key poster presentations at the upcoming 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference taking place in Boston. The presentations focus on Acumen's Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) for the treatment of early AD, including preliminary baseline characteristics of study participants, study participant and partner experience, and treatment expectations and motivations. The conference will be held November 16-19, 2026, both in-person and online. “These presentations reflect Acumen's commitment to understanding the biology of early AD as well as the full experience, including the perspectives of patients and care partners living with it every day,” said Eric Siemers, M.D., Chief Medical Officer of Acumen Pharmaceuticals. “These important insights from our study collaborators and participants in ALTITUDE-AD help keep their needs at the center of our efforts to advance sabirnetug as a potential treatment of choice for AD.”

GlobeNewsWire • Oct 22, 2026

Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026

NEWTON, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report third quarter financial results on Monday, Oct. 26, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

GlobeNewsWire • Oct 19, 2026

4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day

Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.

Zacks Investment Research • Sep 21, 2026

Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day Transcript

Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day Transcript

Seeking Alpha • Sep 16, 2026

Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha • Sep 10, 2026

Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026

NEWTON, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that the Company will host a virtual Investor Day on Wednesday, September 16, 2026 at 10:00 a.m. ET.

GlobeNewsWire • Sep 10, 2026